Replicate Study design for Brazil [Regulatives / Guidelines]

posted by weidson – Brazil, 2018-05-22 18:51 (1064 d 01:54 ago) – Posting: # 18799
Views: 1,751

Dear balakotu

The ANVISA have adopted the EMA's Approach. However, for you use this approach you need to convince them that their drug is highly variable. I hope I have helped you.


Best Regards
Weidson C. de Souza


Edit: Post moved. [Helmut]

Complete thread:

Activity
 Admin contact
21,419 posts in 4,475 threads, 1,510 registered users;
online 5 (0 registered, 5 guests [including 2 identified bots]).
Forum time: Tuesday 20:46 UTC (Europe/Vienna)

We have to remember that what we observe is not nature herself,
but nature exposed to our method of questioning.    Werner Heisenberg

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5